Takeda Pharmaceutical Company Limited (TAK)
TAK trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-03-31, https://www.sec.gov/Archives/edgar/data/1395064/000139506425000095/0001395064-25-000095-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), period ending 2025-03-31. Converted from JPY at 158.4547 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | TAK on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Japan |
| IPO year | 2018 |
| SEC CIK | 0001395064 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $28.9B |
| Net income | $681.1M |
| Operating income | Not in SEC XBRL data |
| Net margin | 2.4% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | 85.9× |
| P/S (computed) | 2.0× |
Reported in JPY; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B2 | 2025-06-27 |
| Latest annual report | 20-F | 2026-06-17 |
| Latest quarterly / interim | 6-K | 2026-09-14 |
Source: SEC EDGAR submissions feed, 704 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.5% |
| 1 month | +1.7% |
| 3 months | +13.6% |
| Year to date | +21.9% |
| 1 year | +38.6% |
| From 52-week high | -0.2% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TEVA | Teva Pharmaceutical Industries Limited | $41.25 | +0.19% | $48.1B |
| REGN | Regeneron Pharmaceuticals Inc. | $753.12 | -1.27% | $77.5B |
| ONC | BeOne Medicines Ltd. | $349.08 | -0.38% | $39.7B |
| GSK | GSK plc | $46.27 | -1.39% | $93.6B |
| SNY | Sanofi ADS | $39.12 | -1.56% | $95.4B |
| RPRX | Royalty Pharma plc Class A Ordinary Shares | $56.57 | -2.09% | $32.5B |
| ZTS | Zoetis Inc. | $74.30 | -1.78% | $30.7B |
| ALNY | Alnylam Pharmaceuticals Inc. | $223.82 | -1.41% | $29.9B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier